Vivalto Partners announces a significant investment in Delbert Pharma in order to support the company’s development in essential medicines and orphan drugs. Historical investors – Sagard NewGen, Socadig Capital Investment, IDIA Capital Investment and MACSF – also reinvest.
Vivalto Partners, Investment company founded in 2021 by Daniel Caille, founder of the group of clinics Vivalto Santé, announces the closing of a significant investment in Delbert Pharma alongside its two founders Marc Childs and Thierry Hoffmann, their management team and all the investors entered in 2020 (Sagard NewGen, Socadif Capital Development, IDIA Capital Investment and MACSF). This investment will allow Delbert Laboratories to reach a new development milestone, to provide them with the means to support this high growth and to contribute to provide an answer to drugs shortage.